Trial · NCT00529373
Results by group449
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 449
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture | Odanacatib 50 mg OW | 1.27 | Parts. w/ fracture per 100 person-years | ||
| Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture | Placebo | 2.74 | Parts. w/ fracture per 100 person-years | ||
| Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated) | Odanacatib 50 mg OW | 0.28 | Parts. w/ fracture per 100 person-years | ||
| Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated) | Placebo | 0.54 | Parts. w/ fracture per 100 person-years | ||
| Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated) | Odanacatib 50 mg OW | 1.85 | Parts. w/ fracture per 100 person-years | ||
| Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated) | Placebo | 2.41 | Parts. w/ fracture per 100 person-years | ||
| Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture | Odanacatib 50 mg OW | 1.33 | Parts. w/ fracture per 100 person-years | ||
| Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture | Placebo | 2.74 | Parts. w/ fracture per 100 person-years | ||
| Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated) | Odanacatib 50 mg OW | 0.29 | Parts. w/ fracture per 100 person-years | ||
| Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated) | Placebo | 0.56 | Parts. w/ fracture per 100 person-years | ||
| Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated) | Odanacatib 50 mg OW | 1.78 | Parts. w/ fracture per 100 person-years | ||
| Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated) | Placebo | 2.41 | Parts. w/ fracture per 100 person-years | ||
| Base Study + First Extension: Rate of Adverse Events | Odanacatib 50 mg OW | 97.25 | 95% Confidence Interval 95.00 to 99.53 | Parts. with event per 100 person-years | |
| Base Study + First Extension: Rate of Adverse Events | Placebo | 96.36 | 95% Confidence Interval 94.13 to 98.63 | Parts. with event per 100 person-years | |
| Base Study + First Extension: Rate of Discontinuations From Study Treatment Due to an Adverse Event | Odanacatib 50 mg OW | 2.66 | 95% Confidence Interval 2.48 to 2.86 | Parts. with event per 100 person-years | |
| Base Study + First Extension: Rate of Discontinuations From Study Treatment Due to an Adverse Event | Placebo | 2.55 | 95% Confidence Interval 2.37 to 2.75 | Parts. with event per 100 person-years | |
| Base Study + First Extension + Second Extension: Percent Change From Baseline in Bone Mineral Density (BMD) Measurements of the Total Hip | Odanacatib 50 mg OW | Month 12 | 3.03 | 95% Confidence Interval 2.91 to 3.14 | Percent change |
| Base Study + First Extension + Second Extension: Percent Change From Baseline in Bone Mineral Density (BMD) Measurements of the Total Hip | Placebo | Month 12 | 1.08 | 95% Confidence Interval 0.95 to 1.22 | Percent change |
| Base Study + First Extension + Second Extension: Percent Change From Baseline in Bone Mineral Density (BMD) Measurements of the Total Hip | Odanacatib 50 mg OW | Month 24 | 4.32 | 95% Confidence Interval 4.18 to 4.46 | Percent change |
| Base Study + First Extension + Second Extension: Percent Change From Baseline in Bone Mineral Density (BMD) Measurements of the Total Hip | Placebo | Month 24 | 0.58 | 95% Confidence Interval 0.42 to 0.74 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00529373/results